Losortan Potassium
Product Images NDC 53808-1072

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 53808-1072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 50mg (Losartan 50mg)

Losartan Potassium 50mg tablets, available in a quantity of 60. This medication is only available with a prescription. The expiration date is January 31, 2015. The manufacturer or distributor's name is not available due to the poor quality of the scan.*

FDA Label Image

Structured Formula For Losartan (Losartanpotasiumtabs Figure 01)

FDA Label Image

Structured Formula For Losartan (Losartanpotasiumtabs Figure 02)

This text appears to be presenting data from a study comparing the effects of two different medications, Atenolol and Losartan Potassium, on a primary endpoint in patients. The study reports an adjusted risk reduction of 13% with a p-value of 0.021. There is also a chart displaying study months and numerical values labeled as "T T R TR R N S B".*

FDA Label Image

Structured Formula For Losartan (Losartanpotasiumtabs Figure 03)

FDA Label Image

Structured Formula For Losartan (Losartanpotasiumtabs Figure 04)

This appears to be a table with various data points including age, risk factors such as high blood pressure, gender, and medical history including diabetes and venereal disease. It seems to be related to a Primary Composite Stroke, which can be fatal or non-fatal. The significance and purpose of this data is not clear.*

FDA Label Image

Structure Product Formula For Losartan (Losartanpotasiumtabs Figure 05)

This appears to be a brief summary of a clinical trial evaluating the efficacy of the drug Losartan Potassium Tablet compared to a placebo in reducing the occurrence of ventricular tachycardia (vt) events in patients. The text indicates that 9% of patients in the study experienced a vt event, and that treatment with Losartan Potassium Tablet resulted in a risk reduction of 16.1%. The value of p was 0.022. There is also a table with three time points: 12, 24, and 48, but it is not clear what these values represent.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.